chemXplore tracks 19 projects in Switzerland, of which 3 are active.
Of the active ones, 2 expansion and 1 new construction.
FDA accepted the sNDA and granted Priority Review for Lynkuet to treat moderate to severe vasomotor symptoms in women on endocrine therapy for HR+ breast cancer.
Emugrobart failed to meet pre-specified weight-loss goals in Phase II GYMINDA; Roche returns rights and the programme will shift toward SMA Phase III while out-licensing is explored.
Interim analysis shows significant, clinically meaningful 24‑hour UPCR reduction at 37 weeks; blinded study continues to the eGFR endpoint at week 105.
Continuous ranibizumab delivery via the Contivue refillable implant offers an alternative to monthly intravitreal injections, with as few as two treatments per year.
Interim analysis shows a significant progression‑free survival benefit versus rituximab+lenalidomide in second‑line or later relapsed/refractory follicular lymphoma; safety as expected.
Boltz foundation models will be applied to ingredient discovery to predict and design scent and flavor molecules using dsm-firmenich’s receptor data, with platform access and embedded researchers.
In-truck sensors, edge computing and machine learning enable continuous quality control and mix optimization in transit, reducing returns and supporting low-carbon mixes across mixer fleets.
Board chair Thomas Leysen will retire; shareholders will vote on Richard Ridinger at an Extraordinary General Meeting on 19 Oct 2026.
Q2 comparable sales roughly flat; EBITDA margin up 80bp; performance-savings target raised to CHF100m; Amsterdam court dismissed Shell and Stichting Ethylene Claims suits.
Adds about 320 stations across Germany, Denmark, Austria and Switzerland; sites to be integrated progressively and will offer HVO biofuel, fast EV charging and convenience formats; subject to approvals.
active / all projects
